Treatment options for small cell lung cancer – do we have more choice?

Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission

1999 • 1,607 citations

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

1999 • 1,394 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer

1992 • 1,295 citations

Small-cell lung cancer

2011 • 1,170 citations

Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer

2007 • 1,015 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

The New Lung Cancer Staging System

2009 • 812 citations

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.

1992 • 802 citations

A phase II study

2000 • 757 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

2006 • 603 citations

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer

2007 • 537 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

MEDICAL RESEARCH COUNCIL COMPARATIVE TRIAL OF SURGERY AND RADIOTHERAPY FOR PRIMARY TREATMENT OF SMALL-CELLED OR OAT-CELLED CARCINOMA OF BRONCHUS

1973 • 528 citations

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

2009 • 507 citations

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

2002 • 487 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer

2004 • 376 citations

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

2007 • 356 citations

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

2006 • 321 citations

A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy

1994 • 309 citations

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer

1994 • 260 citations

Staging and prognostic factors in small cell lung cancer: a consensus report

1989 • 256 citations

Treatment of Brain Metastases of Small-Cell Lung Cancer: Comparing Teniposide and Teniposide With Whole-Brain Radiotherapy—A Phase III Study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

2000 • 239 citations

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

2001 • 236 citations

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

2008 • 236 citations

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

2006 • 227 citations

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

2009 • 204 citations

Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

2007 • 203 citations

Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients

1987 • 200 citations

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

2007 • 197 citations

Gender and Histologic Type Variations in Smoking-Related Risk of Lung Cancer

1992 • 196 citations

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

2009 • 195 citations

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

2007 • 194 citations

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

2005 • 185 citations

Phase II study of imatinib in patients with small cell lung cancer.

2003 • 180 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

2008 • 168 citations

Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

2008 • 164 citations

A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancer

2001 • 159 citations

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein

2005 • 154 citations

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

2009 • 148 citations

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

2005 • 148 citations

Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01

2007 • 142 citations

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

2006 • 140 citations

Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

2009 • 133 citations

Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597

2003 • 120 citations

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

1999 • 114 citations

Staging and clinical prognostic factors for small-cell lung cancer.

2001 • 110 citations

A Meta-Analysis of the Timing of Chest Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer

2004 • 98 citations

Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study

1998 • 95 citations

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial

2006 • 94 citations

Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

2011 • 90 citations

Phase II Trial

1994 • 87 citations

Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

2005 • 86 citations

Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer

2009 • 85 citations

Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

2004 • 83 citations

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

2015 • 82 citations

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients

1993 • 75 citations

Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer

1996 • 74 citations

Recent advances in management of small-cell lung cancer

2004 • 71 citations

Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

1995 • 67 citations

Small-cell lung cancer: treatment progress and prospects.

1998 • 65 citations

Single-agent gemcitabine in patients with resistant small-cell lung cancer

2001 • 65 citations

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

2003 • 61 citations

Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients

2002 • 61 citations

Lung cancer screening: the way forward

2008 • 61 citations

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer

2008 • 61 citations

Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life

2004 • 59 citations

Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update

2004 • 58 citations

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial

2010 • 58 citations

Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer

1993 • 58 citations

First-line chemotherapy rechallenge after relapse in small cell lung cancer

1988 • 54 citations

Second-line chemotherapy in recurrent small cell lung cancer

2004 • 54 citations

Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

2007 • 52 citations

Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy

2008 • 51 citations

CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

2007 • 50 citations

Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

2010 • 49 citations

A Pilot Phase 2 Study of Surgical Treatment After Induction Chemotherapy for Resectable Stage I to IIIA Small Cell Lung Cancer

1997 • 48 citations

High dose etoposide for brain metastases of small cell lung cancer. A phase II study

1989 • 47 citations

Phase II Trial of Imatinib Maintenance Therapy After Irinotecan and Cisplatin in Patients With c-Kit–Positive, Extensive-Stage Small-Cell Lung Cancer

2010 • 45 citations

Current Status of Clinical Trials for Small Cell Lung Cancer

2008 • 45 citations

Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)

2006 • 40 citations

A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group

2007 • 39 citations

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

2016 • 38 citations

Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

2005 • 35 citations

Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer

2007 • 35 citations

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy

2007 • 31 citations

A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer

2008 • 31 citations

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial

2008 • 29 citations

Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial

2008 • 28 citations

Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): A SWOG (S0435) phase II trial

2008 • 28 citations

Topotecan for the treatment of small-cell lung cancer

2007 • 26 citations

Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097)

2008 • 26 citations

Time and chemotherapy treatment trends in the treatment of elderly patients (age ⩾70 years) with small cell lung cancer

2005 • 24 citations

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)

2005 • 23 citations

The proteasome inhibitor PS-341 (bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial

2005 • 22 citations

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion

2008 • 18 citations

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC)

2006 • 18 citations

Chemotherapy strategies in the treatment of small cell lung cancer

2005 • 16 citations

Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group

2006 • 14 citations

Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study

2004 • 14 citations

Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission

2000 • 14 citations

A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy

2008 • 11 citations

Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group

2008 • 8 citations

A phase II trial of amrubicin (AMR) for recurrent or refractory small cell lung cancer (SCLC)

2006 • 4 citations

Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study

2009 • 4 citations

167 CONVERT: Concurrent ONce-daily VErsus twice-daily RadioTherapy. A phase III randomised controlled trial for patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

2012 • 3 citations

CONVERT: Concurrent once-daily versus twice-daily radiotherapy – a new phase III randomised controlled trial for patients with limited-stage small cell lung cancer and good performance status

2009 • 1 citations

Surgery as primary treatment for limited disease small cell lung cancer: Time to re-evaluate

2007 • 1 citations

Clinical outcome of chemoradiotherapy in patients (pts) with limited-disease small-cell lung cancer (LD-SCLC) with ipsilateral pleural effusion

2008 • 1 citations